CHARACTERISTIC | VALUE |
---|---|
Male sex, n (%) | 157 (56.9) |
Median (IQR) age, y* | 60 (47–68) |
Time of warfarin administration, n (%) | |
• Morning | 42 (15.2) |
• Evening | 228 (82.6) |
• Not stated | 6 (2.2) |
Target INR range, n (%) | |
• 2.0–3.0 | 155 (56.2) |
• 2.5–3.5 | 110 (39.9) |
• Other | 11 (4.0) |
History of > 1 critical INR result, n (%) | 136 (49.3) |
Antiplatelet therapy, n (%)† | 132 (47.8) |
Indication for anticoagulation, n (%)‡ | |
• Mechanical heart valve | 128 (46.4) |
-Aortic | 62 (48.4) |
-Mitral | 51 (39.8) |
-Aortic and mitral | 15 (11.7) |
• Venous thromboembolism | 65 (23.6) |
• Atrial fibrillation | 64 (23.2) |
Concurrent medical conditions, n (%)‡ | |
• Atrial fibrillation | 116 (42.0) |
• Hypertension | 112 (40.6) |
• Heart failure | 83 (30.1) |
• Coronary artery disease | 70 (25.4) |
• Stroke or TIA | 67 (24.3) |
• Diabetes (type 1 or 2) | 49 (17.8) |
• Thyroid disorder | 41 (14.9) |
• Renal dysfunction§ | 30 (10.9) |
INR—international normalized ratio, IQR—interquartile range, TIA—transient ischemic attack.
↵* At the time of the most recent critical INR result included in the study.
↵† Includes 1 patient taking dual antiplatelet therapy.
↵‡ Indications and concurrent conditions with < 10% occurrence are not reported.
↵§ Defined as dialysis or serum creatinine level > 200 µmol/L.